A recent publication from the WHO identifies that EU pharmaceutical drug prices are too high and that the process pharmaceutical companies use to determine price is too opaque.
A recent publication from the WHO identifies that EU pharmaceutical drug prices are too high and that the process pharmaceutical companies use to determine price is too opaque.